Updates are available Correction dated 2021-01-05
Click to view Correction: https://doi.org/10.1038/s41586-020-03067-w
-
Authors
Van Nostrand, Eric L. https://orcid.org/0000-0002-5188-0082
Freese, Peter
Pratt, Gabriel A.
Wang, Xiaofeng
Wei, Xintao
Xiao, Rui
Blue, Steven M.
Chen, Jia-Yu https://orcid.org/0000-0001-9449-9321
Cody, Neal A. L.
Dominguez, Daniel
Olson, Sara
Sundararaman, Balaji https://orcid.org/0000-0001-8559-1660
Zhan, Lijun
Bazile, Cassandra
Bouvrette, Louis Philip Benoit
Bergalet, Julie
Duff, Michael O.
Garcia, Keri E.
Gelboin-Burkhart, Chelsea
Hochman, Myles
Lambert, Nicole J.
Li, Hairi
McGurk, Michael P.
Nguyen, Thai B.
Palden, Tsultrim
Rabano, Ines https://orcid.org/0000-0003-4826-4403
Sathe, Shashank
Stanton, Rebecca
Su, Amanda
Wang, Ruth
Yee, Brian A.
Zhou, Bing https://orcid.org/0000-0003-2846-1813
Louie, Ashley L.
Aigner, Stefan https://orcid.org/0000-0002-9511-3328
Fu, Xiang-Dong https://orcid.org/0000-0001-5499-8732
Lécuyer, Eric
Burge, Christopher B. https://orcid.org/0000-0001-9047-5648
Graveley, Brenton R.
Yeo, Gene W.
- License Information
-
More Information
Article History
Received: 22 August 2017
Accepted: 10 July 2019
First Online: 29 July 2020
Change Date: 5 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-020-03067-w
Competing interests
: E.L.V.N. is a co-founder, member of the Board of Directors, equity holder and paid consultant for Eclipse BioInnovations Inc. G.W.Y. is co-founder, member of the Board of Directors, on the SAB, equity holder and paid consultant for Locana and Eclipse BioInnovations Inc. G.W.Y. is a distinguished visiting professor at the National University of Singapore. E.L.V.N.’s and G.W.Y.’s interest(s) have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. C.B.B. is a scientific advisory board member and equity option holder of Arrakis Therapeutics Inc. The authors declare no other competing financial interests.
